RUIPRO 8K HDMI Save money Fiber Optic Cable 48Gbps [email protected] 40ft 4K 2.1 $118 RUIPRO 8K HDMI Fiber Optic Cable 40ft HDMI 2.1 48Gbps [email protected] 4K Electronics Accessories Supplies Audio Video Accessories $118 RUIPRO 8K HDMI Fiber Optic Cable 40ft HDMI 2.1 48Gbps [email protected] 4K Electronics Accessories Supplies Audio Video Accessories [email protected],Cable,Fiber,40ft,$118,8K,Optic,2.1,HDMI,gromeks.ba,4K,48Gbps,Electronics , Accessories Supplies , Audio Video Accessories,/corodiastole2289665.html,RUIPRO,HDMI RUIPRO 8K HDMI Save money Fiber Optic Cable 48Gbps [email protected] 40ft 4K 2.1 [email protected],Cable,Fiber,40ft,$118,8K,Optic,2.1,HDMI,gromeks.ba,4K,48Gbps,Electronics , Accessories Supplies , Audio Video Accessories,/corodiastole2289665.html,RUIPRO,HDMI
Note: Upgraded GEN3 version RUIPRO 8K HDMI Cable is the first true 8K60Hz for long reach HDMI interconnection solution on the market, allowing home theatre, gaming enthusiasts, audio visual users, large venue system designers, installers and home enthusiasts to ensure their cabled infrastructure is ready for HDMI 2.1.
Supports the latest color spaces such as BT.2020 with 10 or more bits per color
Support wider color area, color depth YUV 4:4:4
Good Cable Depends On Good Core, 4-Core Optical Cable amp; 7-Core Copper Cable, Stable And Reliable
|[email protected] or [email protected]||[email protected] enables smooth and sharp viewing of content with high-speed action; [email protected] enables ultra fast-motion UHD images to be crisp and razor sharp â in particular sports, action movies, high-performance gaming and VR benefit significantly|
|Dynamic HDR||Dynamic HDR ensures every moment of a video is displayed at its ideal values for depth, detail, brightness, contrast, and wider color gamuts on a scene-by-scene or even a frame-by-frame basis|
|Ultra High Speed 48gbps||Supports the full range of uncompressed HDMI 2.1 Specification features including 8K video with HDR, Enables up to 48Gbps bandwidth|
|eARC||eARC supports the most advanced high bitrate home theater audio formats, object-based audio, uncompressed 5.1 and 7.1, and 32-channel uncompressed audio; Object-based audio provides an immersive multi-dimensional experience and enhanced audio detail and depth|
|8K 60HZ CL2 Rated Fiber HDMI Cable||4K 60HZ CL2 Rated Fiber HDMI Cable||4K 60HZ HDMI Ultra Thin Fiber Cable||8K 60HZ Fiber HDMI Cable||4K 60HZ Fiber HDMI Cable||8K 60HZ Fiber DisplayPort Cable|
|Resolution||8K60HZ 4K120HZ||4K60HZ||4K60HZ||8K60HZ 4K120HZ||4K60HZ||8K60HZ 4K144HZ|
|ARC/e-ARC||â||â||Limited ARC (only PCM format)||â||â||N/A|
|Connectors||Male to Male||Male to Male||Male to Male||Male to Male||Male to Male||Male to Male|
Lookian et al. describe the development of a third intracranial venous system, the transtentorial venous system using vascular casting, ex vivo micro–computed tomography, and high-resolution magnetic resonance imaging in mice. Image credit: Erina He.
Inhibitors of the renin-angiotensin system (RAS) are widely used to treat hypertension. Using mice harboring fluorescent cell lineage tracers, single-cell RNA-seq, and long-term inhibition of RAS in both mice and humans, we found that deletion of renin or inhibition of the RAS leads to concentric thickening of the intrarenal arteries and arterioles. This severe disease is caused by the multiclonal expansion and transformation of renin cells from a classical endocrine phenotype to a matrix-secretory phenotype: the cells surround the vessel walls and induce the accumulation of adjacent smooth muscle cells and extracellular matrix, resulting in blood flow obstruction, focal ischemia, and fibrosis. Ablation of the renin cells via conditional deletion of β1integrin prevents arteriolar hypertrophy, indicating that renin cells are responsible for vascular disease. Given these findings, prospective morphological studies in humans are necessary to determine the extent of renal-vascular damage caused by the widespread use of inhibitors of RAS.
Hirofumi Watanabe, Alexandre G. Martini, Evan A. Brown, Xiuyin Liang, Silvia Medrano, Shin Goto, Ichiei Narita, Lois J. Arend, Maria Luisa S. Sequeira-Lopez, R. Ariel Gomez
BACKGROUND. Although aberrant glycosylation is recognized as a hallmark of cancer, glycosylation in clinical breast cancer (BC) metastasis has not yet been studied. While preclinical studies show that the glycocalyx coating of cancer cells is involved in adhesion, migration, and metastasis, glycosylation changes from primary tumor (PT) to various metastatic sites remain unknown in patients. METHODS. We investigated N-glycosylation profiles in 17 metastatic BC patients from our rapid autopsy program. Primary breast tumor, lymph node metastases, multiple systemic metastases, and various normal tissue cores from each patient were arranged on unique single-patient tissue microarrays (TMAs). We performed mass spectrometry imaging (MSI) combined with extensive pathology annotation of these TMAs, which enabled spatially differentiated cell-based analysis of N-glycosylation patterns in metastatic BC. RESULTS. N-glycan abundance increased during metastatic progression independent of BC subtype and treatment regimen, with high-mannose glycans most frequently elevated in BC metastases, followed by fucosylated and complex glycans. Bone metastasis, however, displayed increased core-fucosylation and decreased high-mannose glycans. Consistently, N-glycosylated proteins and N-glycan biosynthesis genes were differentially expressed during metastatic BC progression, with reduced expression of EpCAM and mannose-trimming enzymes and elevated N-glycan branching and sialylation enzymes in BC metastases versus PT. CONCLUSION. We show for the first time in patients that N-glycosylation of breast cancer cells undergoing metastasis occurs in a metastatic site-specific manner, supporting the clinical importance of high-mannose, fucosylated, and complex N-glycans as future diagnostic markers and therapeutic targets in metastatic BC. FUNDING. United States National Institutes of Health grants NIH R01CA213428, R01CA213492, T32CA193145, Dutch Province Limburg “LINK”, European Union ERA-NET TRANSCAN2-643638.
Klára Ščupáková, Oluwatobi T. Adelaja, Benjamin Balluff, Vinay Ayyappan, Caitlin M. Tressler, Nicole M. Jenkinson, Britt S.R. Claes, Andrew P. Bowman, Ashley M. Cimino-Mathews, Marissa J. White, Pedram Argani, Ron M.A. Heeren, Kristine Glunde
Tumor necrosis factor (TNF) ligation of TNF receptor 1 (TNFR1) promotes either inflammation and cell survival by inhibiting RIPK1’s death-signaling function and activating NF-kB, or causes RIPK1 to associate with the death-inducing signaling complex to initiate apoptosis or necroptosis. The cellular source of TNF that results in RIPK1-dependent cell death remains unclear. To address this, we employed in vitro systems and murine models of T cell-dependent transplant or tumor rejection in which target cell susceptibility to RIPK1-dependent cell death could be genetically altered. We show that TNF released by T cells is necessary and sufficient to activate RIPK1-dependent cell death in target cells and thereby mediate target cell cytolysis, independent of T cell frequency. Activation of the RIPK1-dependent cell death program in target cells by T cell-derived TNF accelerates murine cardiac allograft rejection and synergizes with anti-PD1 administration to destroy checkpoint blockade-resistant, murine melanoma. Together, the findings uncover a distinct immunological role for TNF released by cytotoxic effector T cells following cognate interactions with their antigenic targets. Manipulating T cell TNF and/or target cell susceptibility to RIPK1-dependent cell death can be exploited to either mitigate or augment T cell-dependent destruction of allografts and malignancies to improve outcomes.
Nicholas Chun, Rosalind L. Ang, Mark Chan, Robert L. Fairchild, William M. Baldwin III, Julian K. Horwitz, Jesse D. Gelles, Jerry Edward Chipuk, Michelle A. Kelliher, Vasile I. Pavlov, Yansui Li, Dirk Homann, Peter S. Heeger, Adrian T. Ting
Glucagon, a hormone released from pancreatic α-cells, plays a key role in maintaining euglycemia. New insights into the signaling pathways that control glucagon secretion may stimulate the development of novel therapeutic agents. In this study, we investigated the potential regulation of α-cell function by G proteins of the Gq family. The use of a chemogenetic strategy allowed us to selectively activate Gq signaling in mouse α-cells in vitro and in vivo. Acute stimulation of α-cell Gq signaling led to elevated plasma glucagon levels, accompanied by increased insulin release and improved glucose tolerance. Moreover, chronic activation of this pathway greatly improved glucose tolerance in obese mice. We also identified an endogenous Gq-coupled receptor (vasopressin 1b receptor; V1bR) that is enriched in mouse and human α-cells. Agonist-induced activation of the V1bR strongly stimulated glucagon release in a Gq-dependent fashion. In vivo studies indicated that V1bR-mediated glucagon release plays a key role in the counter-regulatory hyperglucagonemia under hypoglycemic and glucopenic conditions. These data indicate that α-cell Gq signaling represents an important regulator of glucagon secretion, resulting in multiple beneficial metabolic effects. Thus, drugs that target α-cell enriched Gq-coupled receptors may prove useful to restore euglycemia in various pathophysiological conditions.
Liu Liu, Diptadip Dattaroy, Katherine F. Simpson, Luiz F. Barella, Yinghong Cui, Yan Xiong, Jian Jin, Gabriele M. König, Evi Kostenis, Jefferey C. Roman, Klaus H. Kaestner, Nicolai M. Doliba, Jürgen Wess
The PD-1: PD-L1 is a potent inhibitory pathway involved in immune regulation and a potential therapeutic target in transplantation. In this study, we show that overexpression of PD-1 (PD-1 Tg) on T cells promotes allograft tolerance in a fully MHC-mismatched cardiac transplant model when combined with costimulation blockade (CTLA-4-Ig). PD-1 overexpression on T cells also protected against chronic rejection in a single MHC II mismatched cardiac transplant model, while it still allowed the generation of an effective immune response against an Influenza A virus. Notably, Treg cells from PD-1 Tg mice were required for tolerance induction and presented higher ICOS expression than those from wild-type mice. Survival benefit of PD-1 Tg recipients required ICOS signaling and donor PD-L1 expression. These results indicate that modulation of PD-1 expression, in combination with a costimulation blockade, is a promising therapeutic target to promote transplant tolerance.
Thiago J. Borges, Naoka Murakami, Isadora T. Lape, Rodrigo B. Gassen, Kaifeng Liu, Songjie Cai, Joe Daccache, Kassem Safa, Tetsunosuke Shimizu, Shunsuke Ohori, Alison M. Paterson, Paolo Cravedi, Jamil Azzi, Peter Sage, Arlene Sharpe, Xian C. Li, Leonardo V. Riella
JCI This Month is a digest of the research, reviews, and other features published each month.